News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
EU Extends Review Of Planned Sanofi-Aventis (France) / Zentiva Deal
January 16, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, Jan 16 (Reuters) - The European Commission on Friday extended the deadline for its review of plans by French pharmaceuticals producer Sanofi-Aventis (SASY.PA) to buy Czech generic drugmaker Zentiva (ZNTVsp.PR).
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
Sanofi (France)
MORE ON THIS TOPIC
Business
Elevation Mulls Strategic Alternatives, Including Closure, Amid Activist Pressure
April 18, 2025
·
2 min read
·
Tristan Manalac
Deals
Unusual New Fund Launches to Unlock Some $30B of Capital ‘Trapped’ in Public Biotechs
April 18, 2025
·
3 min read
·
Annalee Armstrong
Tariffs
Biotech’s Next Phase Will Be All-American: Pitchbook
April 17, 2025
·
2 min read
·
Annalee Armstrong
Artificial intelligence
Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics
April 17, 2025
·
2 min read
·
Dan Samorodnitsky